Rentokil Initial’s U.S.-listed ADSs are trading higher as the market continues to price in a more constructive analyst view that has emerged over the past several weeks. A key catalyst in that repricing was Jefferies’ March 12, 2026 upgrade to Buy, which argued the business is at an inflection point and lifted its price target, helping reset near-term expectations for the shares.

The bull case centers on signs of improving operating momentum in North America and a clearer path to unlocking value from the Terminix combination. In its late-February 2026 FY2025 release filed to the SEC, the company reported FY2025 organic revenue growth of 3.0% overall, while North America organic growth was slightly negative for the year, underscoring why investors are sensitive to any evidence that the region is turning the corner.

The next hard catalyst on the calendar is Rentokil’s Q1 trading update on April 16, 2026, which could validate (or challenge) the market’s improving tone on U.S. execution and the integration trajectory. With the stock now trading around the mid-$30s, any incremental commentary on lead flow, customer retention, route density benefits, and cost/integration progress is likely to be the deciding factor for whether the rally can extend.